Quanterix Corporation is engaged in fueling scientific discovery through ultra-sensitive biomarker detection. The Company’s Simoa technology delivers earlier biomarker detection in blood, serum or plasma, with the ability to quantify proteins that are far lower than the level of quantification (LoQ). Its precision instruments, digital immunoassay technology and CLIA-certified Accelerator laboratory have supported research that advances disease understanding and management in neurology, oncology, immunology, cardiology and infectious disease. Its products and services include Simoa Assay Kits, Simoa Dry Blood Extraction Kit, LDTs & Assay Services, Instruments, Simoa Accelerator Laboratory, Homebrew-Custom Assay Development, and Nova Beads. LDTs & Assay Services include Simoa p-Tau 217, Simoa NfL LDT, and LucentAD pTau 217. Its instruments include Simoa HD-X Analyzer-Automated Immunoassays, Quanterix SR-X Biomarker Detection System, and SP-X Imaging and Analysis System.
企業コードQTRX
会社名Quanterix Corp
上場日Dec 07, 2017
最高経営責任者「CEO」Toloue (Masoud)
従業員数471
証券種類Ordinary Share
決算期末Dec 07
本社所在地900 Middlesex Turnpike
都市BILLERICA
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号01821
電話番号16173019400
ウェブサイトhttps://www.quanterix.com/
企業コードQTRX
上場日Dec 07, 2017
最高経営責任者「CEO」Toloue (Masoud)
過去5年間の配当金総支払額は
0.00
米ドルである。

データなし